V itamin A deficiencies (VAD) and vitamin D deficiencies (VDD) have long been considered maladies in the developing world, but recent research demonstrates that children and adults of developed countries also suffer from vitamin deficits (1-4). Individuals with low vitamin levels are particularly vulnerable to infections of the gastrointestinal and respiratory tracts (5-8), the latter of which are responsible for one-fifth of all deaths among children under the age of five (1, 9).
V
itamin A deficiencies (VAD) and vitamin D deficiencies (VDD) have long been considered maladies in the developing world, but recent research demonstrates that children and adults of developed countries also suffer from vitamin deficits (1) (2) (3) (4) . Individuals with low vitamin levels are particularly vulnerable to infections of the gastrointestinal and respiratory tracts (5) (6) (7) (8) , the latter of which are responsible for one-fifth of all deaths among children under the age of five (1, 9) .
Vitamin A is ingested in the form of retinyl esters or betacarotene. It is stored in the liver as an ester and is transported through the circulatory system as retinol bound to the retinol binding protein (RBP) (10) . Upon cellular uptake, retinol is converted to retinal by ubiquitous alcohol dehydrogenases, but further conversion to retinoic acid (RA), an active metabolite of vitamin A, requires specialized aldehyde dehydrogenases (ALDH1A). ALDH1A enzymes are expressed by a subset of cells, including gut dendritic cells and epithelial cells lining the upper and lower respiratory tracts (URT and LRT) (5, 8) . Once converted from retinal, RA in the form of all-trans-RA can be spontaneously isomerized to 9-cis-RA. The two metabolites function as high-affinity ligands, respectively, for the retinoic acid receptor (RAR) and retinoid X receptor (RXR) proteins (11, 12) . RAR and RXR are members of the nuclear receptor superfamily. These exist as monomers, homodimers, and heterodimers. DNA motifs for RAR-RXR binding (known as retinoic acid response elements [RARE] ) are typically direct repeats of half sites puG(G/T)TCA separated by 2 or 5 nucleotides. RA binding to RAR-RXR (and related heterodimeric receptors) can have profound effects on immune cell development, activation, homing, and function (5, (12) (13) (14) .
Vitamin D can be synthesized by the body in addition to being obtained through dietary sources. Cholecalciferol (vitamin D 3 ) and ergocalciferol (vitamin D 2 ) are acquired through the diet, but cholecalciferol is also produced photochemically from 7-dehydrocholesterol in the skin. Cholecalciferol is con- (15, 16) .
Vitamin A and D metabolites are highly interactive. Calcitriol binds the vitamin D receptor (VDR), which like RAR can heterodimerize with RXR (17) . The same DNA binding motifs described for RAR-RXR [puG(G/T)TCA] can be recognized by the VDR-RXR complex, but half sites are often separated by 3 nucleotides (17) rather than 2 or 5. Receptor proteins can bind promiscuously to ligands and to noncanonical DNA motifs. In some instances, vitamin receptors (and related members of the nuclear receptor superfamily) behave synergistically, but in other instances, they antagonize one another (e.g., vitamin D exerts a negative effect on the vitamin A-dependent commitment of bone marrow cells to the granulocytic lineage [13, [17] [18] [19] [20] (23, 24) . These results have important clinical implications, as mucosal IgA may provide a first line of defense against infectious respiratory virus diseases in humans (25) (26) (27) . Although it is not proven, it is possible that individuals with low vitamin levels may respond poorly to influenza virus vaccines in the clinical setting (28) (29) (30) and that they may benefit from vitamin supplementation.
Because the functions of vitamins A and D are related (31), we questioned whether double deficiencies for vitamins A and D would exacerbate impaired IgA responses to an influenza virus vaccine in mice. To do so, we developed animal models for vitamin D deficiency (VDD) and double deficiency (VADϩVDD). Experiments presented here show that VADϩVDD mice were more impaired than VAD or VDD mice in immune responses to the influenza virus vaccine. Moreover, we found that vaccine-induced immune responses can be corrected if vitamins A and D are administered to VADϩVDD mice at the time of vaccination. Pregnant females were maintained on diets throughout their pregnancies and weaned pups were maintained on diets throughout maturation and experimentation. Male and female pups were used. To confirm vitamin depletion, serum samples from vitamin-deficient animals were spot checked for RBP, a surrogate for retinol, by enzyme-linked immunosorbent assay (ELISA) (R&D Systems Mouse RBP4 catalog no. MRBP40, lot no. 327687). Tests were also conducted to measure vitamin D (Michigan University Diagnostic Center for Population and Animal Health [DCPAH], Lansing, MI). All tested mice that were expected to be deficient in vitamin A had RBP levels of Ͻ5,000 ng/ml, while levels in control animals were Ͼ10,000 ng/ml. All tested mice that were expected to be deficient in vitamin D had serum levels of Ͻ15 nmol/liter, while levels in control mice were Ͼ50 nmol/liter (32) .
MATERIALS AND METHODS

Animal
Adult mice of Ͼ6 weeks were used for experimentation. All experiments were repeated to ensure reproducibility. Mice were anesthetized with Avertin and were administered 30 l of a cold-adapted derivative of influenza virus A/Puerto Rico/8/34 (PR8; kindly provided by J. McCullers) by the intranasal (i.n.) route. Virus was prepared by amplification in hen eggs at 33°C. Virus vaccine was at a concentration of 1.25 ϫ 10 9 50% egg infective dose (EID 50 )/ml (33, 34) . Unvaccinated mice served as negative controls. Groups of vaccinated test mice received (i) no vitamin supplement, (ii) vitamin A supplements comprising retinyl palmitate (NutriSorb A; InterPlexus Inc., Kent, WA) at various doses, and/or (iii) liquid vitamin D 3 (cholecalciferol; Pure Encapsulations, Sudbury, MA). Dosing was by oral gavage on day 0 (1ϫ regimen) or on days 0, 3, and 7 (3ϫ regimen) relative to vaccination. Approximately 1 month after vaccination, mice were tested for influenza virus-specific antibody-forming cells (AFCs) or antibodies.
Tissue isolation. Mice were sacrificed with Avertin and exsanguination, confirmed by cervical dislocation. Nasal wash (NW) samples were collected by washing the upper trachea and nasal cavity with 200 l of phosphate-buffered saline (PBS). Bronchoalveolar lavage (BAL) samples were collected by inserting catheters into trachea and washing three times with 1 ml PBS.
To isolate nasal mucosa-associated lymphoid tissue (NALT) and lungs, mice were first perfused with 5 ml PBS injected through the retroorbital sinus. NALT was isolated by removing skin, lower jaws, muscles, cheek bones, and incisors. Remaining snouts were cut into small pieces. Lungs were minced with a razor blade. NALT and lungs were then digested with 4 mg/ml collagenase in PBS at 37°C for 30 min. Lymphocytes were isolated on 75%/40% Percoll gradients as described previously (2,000 rpm in a Beckman Coulter Allegra X-14R centrifuge for 30 min at 25°C) (35) (36) (37) (38) and were washed prior to testing.
ELISA. Vaccine-induced antibodies in NW, BAL fluid, and serum samples from individual mice were tested with an influenza virus- X , for lung AFCs, spots were difficult to count at the highest plated cell concentration (100,000 cells/ well). Counts were therefore taken from wells with fewer cells per well, and AFC values per 100,000 cells were determined mathematically. Means and standard deviations are shown. Experiments were repeated. Group sizes at the completion of this experiment were as follows: control, 5; VDD, 5; VAD, 5; and VADϩVDD, 2. Groups were compared for statistical differences by ANOVA. An asterisk indicates that the designated group differed significantly from all others. Other symbols (ϩ or &) indicate that the group differed significantly from all others except a group with the same symbol. specific ELISA. Wild-type PR8 influenza virus was produced in eggs and was purified by sucrose gradient sedimentation. Purified influenza virus was lysed in disruption buffer (0.05% Triton X-100, 60 mM KCl, 10 mM Tris, pH 7.8) for 5 min at room temperature and was diluted with PBS to 10 g/ml, a stock used for coating 96-well ELISA microtiter plates. Plates were blocked with PBS containing 1% bovine serum albumin (BSA), after which serially diluted test samples were applied. After overnight incubation at 4°C, plates were washed with PBSTween 20 (0.05%). Assay mixtures were next incubated with alkaline phosphatase-conjugated goat anti-mouse IgA (catalog no. 1040-04; Southern Biotech, Birmingham, AL) or goat anti-mouse IgG (IgM and IgA absorbed; catalog no. 1030-04; Southern Biotech) for 1 h at room temperature. Assays were developed with p-nitrophenyl phosphate (catalog no. N2640; Sigma-Aldrich), and optical density measurements were taken at 405 nm. Scores in unvaccinated negative-control mice or in control ELISAs with plates coated only with BSA and no virus were Ͻ0.05.
ELISPOT assay for AFCs. AFCs from NALT and lungs were tested by enzyme-linked immunosorbent spot (ELISPOT) assay. Tissues from each group of mice were pooled and tested in multiple wells. Plates (MultiScreen-IP, catalog no. MAIPS4510; Millipore, Billerica, MA) were coated with purified wild-type PR8 influenza virus at 10 g/ml with 100 l/well. X , for lung AFCs, spots were difficult to count at the highest plated cell concentration (100,000 cells/well). Counts were therefore taken from wells with fewer cells per well, and AFC values per 100,000 cells were determined mathematically. Means and standard deviations are shown. Experiments were repeated. Group sizes at the completion of this experiment were as follows: control, 5; VADϩVDD, 4; VADϩVDDϩvitamin D, 4; VADϩVDDϩvitamin A, 2; and VADϩVDDϩvitamin Dϩvitamin A, 2. Groups were compared for statistical differences by ANOVA. An asterisk with no line indicates that the designated group differed significantly from all others. An asterisk over a line defines a significant difference between two designated groups. Other symbols (ϩ or &) indicate that the group differed significantly from all others except any group with the same symbol.
Plates were incubated for 3 h at 37°C. Wells were next washed with PBS and blocked with a medium containing 10% fetal calf serum (FCS) for 1 h at 37°C. Cells were then applied to the wells (1. After overnight incubation at 4°C, plates were developed with 5-bromo-4-chloro-3-indolylphosphate/nitroblue tetrazolium (BCIP/NBT) substrate (catalog no. B5655; Sigma-Aldrich). Plates were rinsed with water, and spots were counted using a Nikon dissecting scope. Background AFCs with tissues from unvaccinated mice had a value of Յ3 AFCs/100,000 cells. Virus challenge. Vaccinated mice were rested at least 3 weeks and were then challenged with 1 ϫ 10 4 EID 50 wild-type PR8 virus by the i.n. route. Animals were monitored for survival and for return to prechallenge weight 2 weeks after virus infection.
Statistical analyses. ELISA and ELISPOT assay data among groups were compared using analysis of variance (ANOVA) (GraphPad Prism 6 software). In each experiment, all pairwise comparisons were evaluated using Tukey's multiple comparisons tests. Fisher's exact test (GraphPad Prism) was used to evaluate the ability of animals to recover a value of Ն90% prechallenge weight on day 14 postchallenge.
RESULTS
VAD, VDD, VADϩVDD, and control mice were vaccinated with a cold-adapted influenza virus for comparisons of immune responses. After 1 month, NALT and lungs were evaluated by ELISPOT assay to measure responses in the URT and LRT, respectively. As shown in Fig. 1 , the VDD mice were more similar to controls than were other test groups, but AFC levels were significantly lower in the NALT of VDD mice compared to those of controls. VAD animals, as described previously, exhibited poor IgA AFC in NALT and in lungs. IgG responses in VAD animals were affected to a lesser extent than IgA responses (and were in some cases improved compared to controls), resulting in a decrease in the IgA/IgG ratio. Vitamin A was the dominant regulator, but VADϩVDD animals were the most impaired.
We next asked if weak resident antibody responses in the respiratory tracts of VADϩVDD animals could be corrected with vitamin supplementation. We dosed VADϩVDD mice orally with vitamin D, vitamin A, or both on days 0, 3, and 7 relative to vaccination (Fig. 2) . Doses were 600 IU retinyl palmitate and/or 40 IU vitamin D. Vitamin A was again the dominant regulator, particularly for IgA AFC re- X , for lung AFCs, spots were difficult to count at the highest plated cell concentration (100,000 cells/well). Counts were therefore taken from wells with fewer cells per well, and AFC values per 100,000 cells were determined mathematically. Experiments were repeated. Group sizes at the completion of this experiment were as follows: control, 5; VADϩVDD, 2; VADϩVDD ϩ 6/4 1ϫ, 5; VADϩVDD ϩ 60/40 1ϫ, 2; VADϩVDD ϩ 600/40 1ϫ, 4; and VADϩVDD ϩ 600/40 3ϫ, 5. Groups were compared for statistical differences by ANOVA. An asterisk indicates that the designated group differed significantly from all others. An asterisk over a line indicates statistically significant differences between the two designated groups. Other symbols (ϩ, #, or &) indicate that the group differed significantly from all others except any group with the same symbol.
sponses. The best improvements were in VADϩVDD animals that received vitamins A and D as supplements. The degree of correction varied among experiments, and in some experiments, responses in vitamin-supplemented VADϩVDD mice exceeded those of controls.
In a clinical setting, administering vitamin supplements more than once poses logistical difficulties, and very high doses of vitamins, although recommended for use in young children by the World Health Organization (39), can be toxic (40) . We therefore asked if a mixture of vitamins A and D could be administered just once on day 0 rather than three times on days 0, 3, and 7 and if the doses of vitamins could be reduced. We tested groups of VADϩVDD animals with the following regimens of vitamin supplementation: (i) 6 IU vitamin A plus 4 IU vitamin D on day 0 (termed 6/4 1ϫ and most comparable to the recommended daily dose of vitamins by weight in clinical pediatrics [41] ), (ii) 60 IU vitamin A plus 40 IU vitamin D on day 0 (termed 60/40 1ϫ), (iii) 600 IU vitamin A plus 40 IU vitamin D on day 0 (termed 600/40 1ϫ), and (iv) 600 IU vitamin A plus 40 IU vitamin D on days 0, 3, and 7 (termed 600/40 3ϫ). Vitamin formulations in mice were tested with an understanding that the vitamin A content in a standard laboratory mouse diet is more than 10-fold that recommended for humans by weight (41) and that when vitamin A content is reduced in the C57BL/6 mouse diet, there is a significant fall in retinol equivalents in the kidney (32) .
As shown in Fig. 3 , the 600/40 1ϫ and 600/40 3ϫ regimens each sufficed to enhance IgA and IgG responses in NALT and lungs following vaccination with the cold-adapted influenza virus vaccine. In some cases, responses in supplemented animals exceeded those of controls. When smaller amounts of vitamins were tested in VADϩVDD groups, we found that the lowest dose (6/4 1ϫ) was sufficient to correct IgG AFC but not IgA AFC in the NALT and lungs. Altogether, results demonstrated that vitamin A and D supplements administered with influenza virus vaccination assisted vaccine-induced immune responses in VADϩVDD animals in a dose-dependent manner and that IgG was easier to correct than IgA.
To determine if the virus-specific AFC results predicted virus-specific antibody responses in VADϩVDD animals, we measured antibodies in the serum samples, NW, and BAL fluid of test and control mice. As shown in Fig. 4A , IgG responses in serum samples were not significantly impaired in VADϩVDD animals compared to those in controls, which is similar to the situation for VAD animals described previously (42) . IgA antibody levels, like IgA AFC levels, were significantly reduced in VADϩVDD animals compared to those in controls (Fig. 4B  and D) . However, unlike the situation for AFC levels, the IgG antibody levels in NW and BAL fluid did not drop significantly in VADϩVDD mice ( Fig. 4C and E) . This is likely because serum IgG is readily transmitted to the respiratory tract and particularly the LRT (43, 44) . Figure 5 shows antibody results following vitamin supplementation of VADϩVDD mice. Similar to the situation for AFC (Fig.  3) , the lowest dose of vitamins (6/4) heightened IgG responses better than IgA responses in the VADϩVDD animals. Higher vitamin doses were required for full correction of IgA. Upper (NW) and lower (BAL fluid) respiratory tract antibodies were improved and sometimes exceeded the levels of controls. The highest dose of vitamins, administered one or three times, yielded the highest antibody levels in URT and LRT secretions.
To determine how vitamin-deficient mice would fare following a lethal challenge with wild-type influenza virus after vaccination, we vaccinated animals, rested animals for at least 3 weeks, and then infected animals with wild-type PR8. We found that some vaccinated control mice lost weight after this challenge but then cleared the virus and recovered prevaccination weight (to a level of Ն90%) within a 2-week time period. The majority of mice in the VADϩVDD group also cleared the virus (not shown) and recovered Ն90% prechallenge weight by day 14 (Fig. 6A) . In one experiment (experiment 1), there were more deaths among VADϩVDD mice compared to those among controls ( Fig. 6A and  B) . Overall, there were fewer VADϩVDD animals that recovered Ն90% of their weight by day 14 postchallenge compared to controls. Subtleties in group differences likely reflected the retention by vitamin-deficient mice of serum IgG, which may have assisted in virus clearance (43, 44) . 
DISCUSSION
Here we describe three mouse models of vitamin deficiencies to compare mucosal and systemic immune responses generated against an i.n. cold-adapted influenza virus vaccine. Results revealed a significant impairment of vaccine-induced respiratory antibody responses in VADϩVDD mice. Vitamin A was the dominant regulator, but responses were lowest when animals were deficient for vitamins A and D. The AFC responses in the URT and LRT were not entirely predictive of antibody responses, and the loss of IgG was less extreme than the loss of IgA. This was likely because serum IgG antibody was sustained in vitamin-deficient animals and may have been transmitted to URT and LRT tissues (43, 44) . The serum antibody activities also may have assisted in protection, as vaccinated VADϩVDD animals were usually, but not always, protected from virus challenge. Overall, a return to Ն90% prechallenge weight was less frequent in VADϩVDD animals than it was in controls. We further showed that if VADϩVDD animals were supplemented with vitamins A and D at the time of vaccination, influenza virus-specific responses could be restored. The vitamin levels required for correction of antibody responses were lower for IgG than for IgA. Supplementation with vitamin A had a greater corrective effect than supplementation with vitamin D, and best results were with the two vitamins combined. How do vitamins influence antibody production? We have observed in an in vitro system of B cell activation that interleukin-6 (IL-6) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are upregulated in the presence of vitamin A and that IgA production is dependent upon these cytokines (45) . Similarly, vitamin A has been shown to enhance transforming growth factor ␤ (TGF-␤), which triggers IgA production by activated B cells (46) . Mechanisms of vitamin influences on the immune response are complex, as cytokine production, innate immune cell activation, cell integrity, antigen presentation, and lymphocyte cell homing to mucosal surfaces are all affected by vitamin levels (5). We have recently discovered hot spots for vitamin receptor DNA binding motifs in the switch (S) regions of murine and human immunoglobulin heavy chain genes (particularly S, Sε, and S␣, but rarely S␥), which suggests that there may be direct and indirect influences of vitamins on class switch recombinations (CSR) and on B cell antibody isotype expression patterns (47) . Hot spots for DNA binding motifs of related nuclear receptors (e.g., estrogen receptors) are also found in S regions, perhaps explaining, in part, the complexity of vitamin influences on their target genes (e.g., males and females respond differently to vitamin supplementation [48] ).
Vitamins A and D are each known for their positive effects on the human immune response to viral disease (6, 29, 49) . In a recent clinical study, we found that vitamin insufficiencies or deficiencies were prevalent in an inner city of the United States and that vitamin A (measured using RBP as the surrogate [10] ) correlated with serum IgA, serum IgG4, and influenza virus-specific neutralizing antibodies; vitamin D was associated with serum IgM and IgG3 (50) . A clinical study of vitamin levels or supplements in the context of an i.n. respiratory virus vaccine has never been performed. Previous studies have exhibited benefits of vitamin supplementation in the context of other vaccination programs, but results have been inconsistent (30, 51, 52) . This may be because (i) previous clinical studies have focused largely on vitamin A or vitamin D without consideration of cross-regulatory capacities, and (ii) vitamin supplementation studies were often conducted without measurement of incoming vitamin levels; some participants may have been vitamin replete and negatively impacted by high vitamin doses (48, 53) . With these caveats in mind, our results and previous literature encourage careful clinical tests of vitamin A and D supplements in vitamin insufficient and deficient recipients of i.n. influenza virus vaccines.
Though our mouse studies are informative, the selection of a best dose for vitamin supplementation in humans will require empirical testing. Benefits and risks must be contemplated upon clinical trial design (48, 54) , as an overzealous immune response in the respiratory tract, particularly if comprising T cell responses in the absence of neutralizing antibodies, can lead to a cytokine storm and obstructed airways (55) . It is unlikely that the doses described in mice can be directly translated to humans, in part because a normal mouse diet (as was received by control animals in our experiments) contains more than 10 times the recommended daily allowance in humans by weight (41) . Our mouse model also differs from humans in that VADϩVDD mice were deprived of all dietary vitamin A and vitamin D from day 5 gestation until maturity, whereas humans, even in cases of severe deficiencies, might receive some level of vitamins. Despite these recognized differences, mouse data instruct clinical trial design by showing that (i) supplements administered on day 0 alone (or on days 0, 3, and 7) were sufficient to support significant recovery of IgG and IgA responses, and (ii) greater improvements in IgA and IgG responses were observed with increasing doses of vitamins A and D. Supplements may ultimately improve responses to influenza virus vaccines in children and adults who are vitamin deficient and may ultimately improve defenses against respiratory viral disease.
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